

***In the Claims:***

This listing of claims will replace all prior versions, and listings, of claims in the application.

23. (Currently Amended) A dispenser comprising a reservoir containing an oral formulation for a controlled drug or drug of abuse presented in a format such that:

- (a) a patient's access to the oral formulation is controlled; and
- (b) the patient's access to the oral formulation is monitored in real time;

such that the control over the patient's usage of the oral formulation does not require the supervision of a healthcare professional at the time of administration.

24. (Previously presented) The dispenser as claimed in claim 23, wherein the controlled drug or drug of abuse is a class A drug in a non-intravenous formulation, as defined by The Misuse of Drugs Act 1971.

25. (Previously presented) The dispenser as claimed in claim 23, wherein the controlled drug or drug of abuse is an opioid.

26. (Previously presented) The dispenser as claimed in claim 25, wherein the opioid is methadone or a pharmaceutically acceptable salt or derivation thereof.

27. (Previously presented) The dispenser as claimed in claim 26, wherein the opioid is methadone hydrochloride.

28. (Cancelled)

29. (Previously presented) The dispenser as claimed in claim 25, wherein the opioid is diamorphine or a pharmaceutically acceptable salt or derivative thereof.

30. (Previously presented) The dispenser as claimed in claim 29, wherein the opioid is diamorphine hydrochloride.

31. (Previously presented) The dispenser as claimed in claim 29, wherein the diamorphine is dry and suitable for nasal delivery upon mixing with an aqueous solution.

32. (Previously presented) The dispenser as claimed in claim 31, wherein the formulation for nasal delivery further comprises a solubility enhancer.

33. (Previously presented) The dispenser as claimed in claim 32, wherein the solubility enhancer is one or more of caffeine, sodium benzoate and sodium salicylate.

34. (Previously presented) The dispenser as claimed in claim 32, wherein the solubility enhancer comprises caffeine, sodium benzoate, sodium salicylate, or a combination thereof.

35. (Previously presented) The dispenser as claimed in claim 31, wherein the formulation for nasal delivery is a freeze-dried formulation.

36. (Previously presented) The dispenser as claimed in claim 23, wherein a number of doses of the formulation are stored within the reservoir to be supplied to the patient.

37. (Currently amended) A dispenser comprising a reservoir containing a plurality of dosage units each of which comprise an oral formulation of a controlled drug or drug of abuse, said dosage units being contained in a tamper-evident manner such that:

- (a) a patient's access to the dosage units is controlled; and
- (b) the patient's access to the dosage units is monitored in real time;

such that the control over the patient's usage of the oral formulation does not require the supervision of a healthcare professional at the time of administration.

38. (Currently amended) The dispenser of claim 37, wherein more than 1 day's supply of dosage ~~[[unites]]~~ units are contained in the dispenser.